This webinar is looking at the published literature which has reported on differences in the performance characteristics of the two LBC preservatives SurePath and ThinPrep: Interfering substances and LBC performance Unsatisfactory rates Glandular disease detection Both LBCs are in widespread use in the USA, UK, etc. Recently, data from the national cancer screening programs of the UK, Denmark and the Netherlands have been analyzed to evaluate the impact of liquid-based cytology following replacement of the conventional Pap smear. However, there are no published randomized controlled clinical trials that directly compare SurePath and ThinPrep in a general screening setting. These
To view full content, log in using the links below.